Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Anthracyclines and taxanes are cytotoxic agents that are commonly used for the treatment of breast cancer, including in the adjuvant, neoadjuvant, and metastatic setting. Each drug class of is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agents have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps in patients with rapidly progressive disease and/or high tumor burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DOX belongs to phase-specific anthracyclines and is a compound used clinically in the treatment of many types of cancer, including breast cancer.28”
From A layered cancer-on-a-chip system for anticancer drug screening and disease modeling (2023) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Bangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Self-citationIniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett, W. K., Huang, P., Xu, Y.-Z., Heinemann, V., Grunewald, R., & Gandhi, V. V. (1995) · PubMed · Cited by 753
Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2197 · Cited by 738
Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 641
Giordano, S. H., Buzdar, A. U., Smith, T. L., Kau, S., Yang, Y., & Hortobagyi, G. N. (2004) · Cancer · doi:10.1002/cncr.11859 · Cited by 540
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Mechanism of Action of Camptothecin
Liu, L. F., Duann, P., Lin, C., D'Arpa, P., & Wu, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26375.x · Cited by 508
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Mechanism of Action of Camptothecin
LIU, L. F., DESAI, S. D., LI, T., MAO, Y., SUN, M., & SIM, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07020.x · Cited by 476
Chia, S. K., Speers, C. H., D'yachkova, Y., Kang, A., Malfair‐Taylor, S., Barnett, J., Coldman, A., Gelmon, K. A., O'Reilly, S. E., & Olivotto, I. A. (2007) · Cancer · doi:10.1002/cncr.22867 · Cited by 465
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Perez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Epothilones: Mechanism of Action and Biologic Activity
Goodin, S., Kane, M. P., & Rubin, E. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.001 · Cited by 346
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 305
Vahdat, L. T., Pruitt, B., Fabian, C. J., Rivera, R. R., Smith, D. A., Tan-Chiu, E., Wright, J., Tan, A. R., DaCosta, N. A., Chuang, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7618 · Cited by 244
Sparano, J. A., Vrdoljak, E., Rixe, O., Xu, B., Manikhas, A., Medina, C., Ventilari Da Costa, S. C., Ro, J., Rubio, G., Rondinon, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4244 · Cited by 218
Self-citationCortes, J., Vahdat, L., Blum, J. L., Twelves, C., Campone, M., Roché, H., Bachelot, T., Awada, A., Paridaens, R., Goncalves, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8467 · Cited by 214
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Bajetta, E., Procopio, G., Celio, L., Gattinoni, L., Della Torre, S., Mariani, L., Catena, L., Ricotta, R., Longarini, R., Zilembo, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.167 · Cited by 207
Tevaarwerk, A. J., Gray, R. J., Schneider, B. P., Smith, M. L., Wagner, L. I., Fetting, J. H., Davidson, N., Goldstein, L. J., Miller, K. D., & Sparano, J. A. (2013) · Cancer · doi:10.1002/cncr.27819 · Cited by 196
Self-citationDawood, S., Broglio, K., Gonzalez-Angulo, A. M., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1168 · Cited by 187
Martín, M., Ruiz, A., Muñoz, M., Balil, A., García-Mata, J., Calvo, L., Carrasco, E., Mahillo, E., Casado, A., García-Saenz, J. Á., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70041-4 · Cited by 187
BRCA mutations in the management of breast cancer: the state of the art
Narod, S. A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.166 · Cited by 161
Cardoso, F., Leo, A. D., Lohrisch, C. A., Bernard, C., Ferreira, F., & Piccart, M. J. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf101 · Cited by 146
Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., Zheng, W., Seletsky, B. M., Zhu, X., Lewis, B. M., Kishi, Y., Yu, M. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1874 · Cited by 141
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
Aogi, K., Iwata, H., Masuda, N., Mukai, H., Yoshida, M., Rai, Y., Taguchi, K., Sasaki, Y., & Takashima, S. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr444 · Cited by 127
Perez, E. A., Hillman, D. W., Mailliard, J. A., Ingle, J. N., Ryan, J. M., Fitch, T. R., Rowland, K. M., Kardinal, C. G., Krook, J. E., Kugler, J. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.047 · Cited by 121
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S., Parker, S., Thornton, C. E., Ghersi, D., Simes, J., & Wilcken, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub2 · Cited by 118
Sparano, J. A., Makhson, A. N., Semiglazov, V. F., Tjulandin, S. A., Balashova, O. I., Bondarenko, I. N., Bogdanova, N. V., Manikhas, G. M., Oliynychenko, G. P., Chatikhine, V. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5013 · Cited by 116
Self-citationPlatinum-containing regimens for metastatic breast cancer
Egger, S. J., Willson, M. L., Morgan, J. L., Walker, H. S., Carrick, S. E., Ghersi, D., & Wilcken, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003374.pub4 · Cited by 91
Robert, N. J., Vogel, C. L., Henderson, I. C., Sparano, J. A., Moore, M. R., Silverman, P., Overmoyer, B. A., Shapiro, C. L., Park, J. W., Colbern, G. T., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.09.018 · Cited by 79
Self-citationKanter, P. M., Bullard, G. A., Ginsberg, R., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R., & Pavelic, Z. P. (1993) · PubMed · Cited by 74
Traina, T. A., Theodoulou, M., Feigin, K., Patil, S. N., Tan, K. L., Edwards, C., Dugan, U., Norton, L., & Hudis, C. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8388 · Cited by 70
Fojo, T., & Coley, H. M. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.035 · Cited by 69
Kanter, P. M., Bullard, G. A., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R., & Pavelic, Z. P. (1993) · PubMed · Cited by 68
A unified definition of clinical anthracycline resistance breast cancer
Pivot, X. B., Asmar, L., Buzdar, A. U., Valero, V., & Hortobágyi, G. N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0958 · Cited by 47
Platinum containing regimens for metastatic breast cancer
Carrick, S. E., Ghersi, D., Wilcken, N., & Simes, J. R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003374.pub3 · Cited by 45
Drug candidates derailed in case of mistaken identity
Ledford, H. K. (2012) · Nature · doi:10.1038/483519a · Cited by 29
Kardinal, C. G., Perry, M. C., WEINBERG, V. K., Wood, W., Ginsberg, S. J., Raju, R. N., & Cancer and Leukemia Group B (1983) · Breast Cancer Research and Treatment · doi:10.1007/bf01807589 · Cited by 26
Roche, H. H., Conte, P., Perez, E. A., Sparano, J. A., Xu, B., Jassem, J., Peck, R., Kelleher, T., & Hortobágyi, G. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1251-y · Cited by 25
Self-citationRetreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy
Castiglione‐Gertsch, M., Tattersall, M., Hacking, A., Goldhirsch, A., Gudgeon, A., Gelber, R. D., Lindtner, J., Coates, A. S., Collins, J., Isley, M., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10011-9 · Cited by 21
Guo, X., Loibl, S., Untch, M., Möbus, V. J., Schwedler, K., Fasching, P. A., Barinoff, J., Holms, F., Thomssen, C., Zahm, D. M., et al. (2011) · Breast Care · doi:10.1159/000330946 · Cited by 19
Guo, J., Meng, H., Pei, J., & Zhu, M. (2011) · Breast Care · doi:10.1159/000327515 · Cited by 15
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
Gale, S., & Croasdell, G. (2010) · PubMed · Cited by 13
Cited by
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., & Cortes, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4892 · Cited by 463
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
Yang, S. X., Polley, E., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 237
Twelves, C., Cortes, J., Vahdat, L., Olivo, M., He, Y., Kaufman, P. A., & Awada, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3144-y · Cited by 217
Emerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 172
Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells
Chen, K., Shou, L., Lin, F., Duan, W., Wu, M., Xie, X., Xie, Y., Li, W., & Tao, M. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000089 · Cited by 109
Metadata
- Authors
- Andreopoulou, E., & Sparano, J. A.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Sparano, Joseph A.
- ORCID
- Sparano, Joseph A.
- Venue
- Current Breast Cancer Reports
- Published
- 2013-01-05
- Volume
- 5
- Issue
- 1
- Pages
- 42-50
- ISSN
- 1943-4588 (ISSN-L)
- 1943-4596
- PMC
- PMC3579672
- OpenAlex
- W2033274910
- Cited by
- 65
- References
- 61
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 4 · 2016: 10 · 2015: 5 · 2014: 5 · 2013: 3
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Breast Cancer Reports (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U10CA014958)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- metastatic breast cancer, anthracycline pretreated, second-line chemotherapy, anthracycline cardiotoxicity, vinorelbine, ixabepilone, eribulin, capecitabine, gemcitabine, irinotecan, topoisomerase I inhibitor, platinum analogues, liposomal doxorubicin, single-agent chemotherapy, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.